Cellular therapy and induced neuronal replacement for Huntington's disease

Area of Science:

• Neuroscience
• Genetics
• Cell Biology

Background:

• Huntington's disease (HD) is an inherited, progressive neurodegenerative disorder characterized by neuronal loss, choreiform movements, cognitive decline, and emotional lability.
• The disease results from an expanded CAG tri-nucleotide repeat in the Huntingtin gene, leading to polyglutamine (polyQ) protein aggregation and selective medium spiny neuron degeneration.
• Current therapeutic strategies focus on mitigating mutant huntingtin toxicity and metabolic impairment to delay neuronal degeneration.

Purpose of the Study:

• To review recent advancements in cell transplantation therapies for Huntington's disease.
• To explore emerging sources of human striatal progenitor cells for transplantation.
• To discuss the potential of gene therapy for inducing neurogenesis and neuronal recruitment in the context of HD treatment.

Main Methods:

• Review of current literature on cell transplantation and gene therapy for Huntington's disease.
• Analysis of progress in fetal striatal cell transplantation and alternative progenitor cell sources.
• Evaluation of gene therapy approaches for stimulating endogenous neurogenesis.

Main Results:

• Cell replacement therapy, including fetal striatal cell transplantation, is a promising avenue for later stages of HD.
• Emerging alternative sources of human striatal progenitor cells are being investigated for transplantation.
• Gene therapy holds potential for inducing striatal neurogenesis and neuronal recruitment.

Conclusions:

• Cell replacement and gene therapy represent significant potential therapeutic strategies for Huntington's disease, particularly in later disease stages.
• Further research into progenitor cell sources and gene therapy applications is crucial for clinical translation.
• These approaches aim to address neuronal loss and restore function in HD patients.